Diabetes medication, including oral antidiabetic agents (OADs) (α-glucosidase inhibitors, biguanides, meglitinide, thiazolidinedione, sulfonylurea, dipeptidyl peptidase 4 [DPP4] inhibitors and sodium-glucose co-transporter-2 [SGLT-2] inhibitors), insulin and glucagon-like peptide-1 receptor agonists were documented during the study period according to pharmacological and Anatomical Therapeutic Chemical (ATC) classification. The gene discussed is DPP4; the disease is diabetes mellitus.